nodes	percent_of_prediction	percent_of_DWPC	metapath
Lenalidomide—TNFSF11—embryo—polycystic ovary syndrome	0.0295	0.0782	CbGeAlD
Lenalidomide—PTGS2—ovarian follicle—polycystic ovary syndrome	0.0284	0.0752	CbGeAlD
Lenalidomide—CDH5—embryo—polycystic ovary syndrome	0.0222	0.0588	CbGeAlD
Lenalidomide—CDH5—adrenal cortex—polycystic ovary syndrome	0.0182	0.0482	CbGeAlD
Lenalidomide—TNFSF11—adrenal gland—polycystic ovary syndrome	0.0174	0.0462	CbGeAlD
Lenalidomide—CDH5—endometrium—polycystic ovary syndrome	0.0162	0.043	CbGeAlD
Lenalidomide—CDH5—Cell junction organization—CDH15—polycystic ovary syndrome	0.0152	0.0437	CbGpPWpGaD
Lenalidomide—TNFSF11—endocrine gland—polycystic ovary syndrome	0.0151	0.0401	CbGeAlD
Lenalidomide—CDH5—uterus—polycystic ovary syndrome	0.015	0.0396	CbGeAlD
Lenalidomide—CDH5—pituitary gland—polycystic ovary syndrome	0.0147	0.0389	CbGeAlD
Lenalidomide—CDH5—adipose tissue—polycystic ovary syndrome	0.0146	0.0388	CbGeAlD
Lenalidomide—CRBN—embryo—polycystic ovary syndrome	0.0141	0.0374	CbGeAlD
Lenalidomide—Gastrointestinal tract irritation—Metformin—polycystic ovary syndrome	0.0133	0.0492	CcSEcCtD
Lenalidomide—CDH5—adrenal gland—polycystic ovary syndrome	0.0131	0.0348	CbGeAlD
Lenalidomide—TNFSF11—IL6-mediated signaling events—GAB1—polycystic ovary syndrome	0.0129	0.0372	CbGpPWpGaD
Lenalidomide—CDH5—Signaling by VEGF—FLT4—polycystic ovary syndrome	0.0128	0.0369	CbGpPWpGaD
Lenalidomide—CDH5—Cell junction organization—CLDN4—polycystic ovary syndrome	0.0124	0.0357	CbGpPWpGaD
Lenalidomide—PTGS2—Nicotinate metabolism—NMNAT3—polycystic ovary syndrome	0.0124	0.0356	CbGpPWpGaD
Lenalidomide—CDH5—female gonad—polycystic ovary syndrome	0.0122	0.0324	CbGeAlD
Lenalidomide—CDH5—vagina—polycystic ovary syndrome	0.0122	0.0322	CbGeAlD
Lenalidomide—CRBN—adrenal cortex—polycystic ovary syndrome	0.0115	0.0306	CbGeAlD
Lenalidomide—CDH5—endocrine gland—polycystic ovary syndrome	0.0114	0.0302	CbGeAlD
Lenalidomide—CDH5—Cell-Cell communication—CDH15—polycystic ovary syndrome	0.0108	0.0311	CbGpPWpGaD
Lenalidomide—CRBN—endometrium—polycystic ovary syndrome	0.0103	0.0273	CbGeAlD
Lenalidomide—Sinus congestion—Metformin—polycystic ovary syndrome	0.00958	0.0353	CcSEcCtD
Lenalidomide—CRBN—uterus—polycystic ovary syndrome	0.0095	0.0252	CbGeAlD
Lenalidomide—CRBN—pituitary gland—polycystic ovary syndrome	0.00933	0.0247	CbGeAlD
Lenalidomide—CRBN—adipose tissue—polycystic ovary syndrome	0.00929	0.0246	CbGeAlD
Lenalidomide—Azotaemia—Metformin—polycystic ovary syndrome	0.00895	0.033	CcSEcCtD
Lenalidomide—CDH5—Cell-Cell communication—CLDN4—polycystic ovary syndrome	0.00882	0.0254	CbGpPWpGaD
Lenalidomide—Loose stools—Metformin—polycystic ovary syndrome	0.00861	0.0317	CcSEcCtD
Lenalidomide—CRBN—adrenal gland—polycystic ovary syndrome	0.00834	0.0221	CbGeAlD
Lenalidomide—TNFSF11—RANKL/RANK Signaling Pathway—TAB1—polycystic ovary syndrome	0.00826	0.0237	CbGpPWpGaD
Lenalidomide—Toothache—Metformin—polycystic ovary syndrome	0.00783	0.0289	CcSEcCtD
Lenalidomide—CRBN—female gonad—polycystic ovary syndrome	0.00777	0.0206	CbGeAlD
Lenalidomide—CRBN—vagina—polycystic ovary syndrome	0.00773	0.0205	CbGeAlD
Lenalidomide—PTGS2—Nicotinamide salvaging—NAMPT—polycystic ovary syndrome	0.00773	0.0222	CbGpPWpGaD
Lenalidomide—Respiratory distress—Metformin—polycystic ovary syndrome	0.0075	0.0277	CcSEcCtD
Lenalidomide—CDH5—Signaling events mediated by VEGFR1 and VEGFR2—GAB1—polycystic ovary syndrome	0.00729	0.021	CbGpPWpGaD
Lenalidomide—Upset stomach—Metformin—polycystic ovary syndrome	0.00727	0.0268	CcSEcCtD
Lenalidomide—CRBN—endocrine gland—polycystic ovary syndrome	0.00723	0.0192	CbGeAlD
Lenalidomide—CDH5—S1P2 pathway—IRS1—polycystic ovary syndrome	0.00695	0.02	CbGpPWpGaD
Lenalidomide—TNFSF11—IL6-mediated signaling events—CRP—polycystic ovary syndrome	0.00654	0.0188	CbGpPWpGaD
Lenalidomide—Fungal infection—Metformin—polycystic ovary syndrome	0.00617	0.0228	CcSEcCtD
Lenalidomide—CDH5—VEGFR2 mediated vascular permeability—AKT2—polycystic ovary syndrome	0.00606	0.0174	CbGpPWpGaD
Lenalidomide—Rhinorrhoea—Metformin—polycystic ovary syndrome	0.00588	0.0217	CcSEcCtD
Lenalidomide—Rigors—Metformin—polycystic ovary syndrome	0.00584	0.0215	CcSEcCtD
Lenalidomide—Contusion—Metformin—polycystic ovary syndrome	0.00546	0.0201	CcSEcCtD
Lenalidomide—TNFSF11—Differentiation Pathway—INS—polycystic ovary syndrome	0.00537	0.0155	CbGpPWpGaD
Lenalidomide—TNFSF11—Differentiation Pathway—IGF1—polycystic ovary syndrome	0.0052	0.0149	CbGpPWpGaD
Lenalidomide—TNFSF11—RANKL/RANK Signaling Pathway—AKT2—polycystic ovary syndrome	0.00466	0.0134	CbGpPWpGaD
Lenalidomide—Neuropathy—Metformin—polycystic ovary syndrome	0.00448	0.0165	CcSEcCtD
Lenalidomide—PTGS2—Nicotinate metabolism—NAMPT—polycystic ovary syndrome	0.00411	0.0118	CbGpPWpGaD
Lenalidomide—Ear pain—Metformin—polycystic ovary syndrome	0.00406	0.015	CcSEcCtD
Lenalidomide—PTGS2—embryo—polycystic ovary syndrome	0.00384	0.0102	CbGeAlD
Lenalidomide—ABCB1—ABC-family proteins mediated transport—ABCB6—polycystic ovary syndrome	0.00382	0.011	CbGpPWpGaD
Lenalidomide—Thalidomide—CYP1A1—polycystic ovary syndrome	0.00381	1	CrCbGaD
Lenalidomide—Nasal congestion—Metformin—polycystic ovary syndrome	0.0038	0.014	CcSEcCtD
Lenalidomide—PTGS2—Prostaglandin Synthesis and Regulation—PTGER3—polycystic ovary syndrome	0.0037	0.0107	CbGpPWpGaD
Lenalidomide—Hypoglycaemia—Metformin—polycystic ovary syndrome	0.00355	0.0131	CcSEcCtD
Lenalidomide—Lethargy—Metformin—polycystic ovary syndrome	0.00353	0.013	CcSEcCtD
Lenalidomide—Pain in extremity—Metformin—polycystic ovary syndrome	0.00346	0.0128	CcSEcCtD
Lenalidomide—Migraine—Metformin—polycystic ovary syndrome	0.00341	0.0126	CcSEcCtD
Lenalidomide—TNFSF11—Differentiation Pathway—VEGFA—polycystic ovary syndrome	0.0034	0.00976	CbGpPWpGaD
Lenalidomide—Dehydration—Metformin—polycystic ovary syndrome	0.00322	0.0119	CcSEcCtD
Lenalidomide—Liver function test abnormal—Metformin—polycystic ovary syndrome	0.00319	0.0118	CcSEcCtD
Lenalidomide—PTGS2—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—AKR1C3—polycystic ovary syndrome	0.00316	0.00909	CbGpPWpGaD
Lenalidomide—Abdominal pain upper—Metformin—polycystic ovary syndrome	0.00316	0.0117	CcSEcCtD
Lenalidomide—PTGS2—adrenal cortex—polycystic ovary syndrome	0.00314	0.00834	CbGeAlD
Lenalidomide—Breast disorder—Metformin—polycystic ovary syndrome	0.00313	0.0115	CcSEcCtD
Lenalidomide—Cramp muscle—Metformin—polycystic ovary syndrome	0.00312	0.0115	CcSEcCtD
Lenalidomide—Nasopharyngitis—Metformin—polycystic ovary syndrome	0.00309	0.0114	CcSEcCtD
Lenalidomide—Abdominal distension—Metformin—polycystic ovary syndrome	0.00301	0.0111	CcSEcCtD
Lenalidomide—Influenza—Metformin—polycystic ovary syndrome	0.00299	0.011	CcSEcCtD
Lenalidomide—Pancreatitis—Metformin—polycystic ovary syndrome	0.00293	0.0108	CcSEcCtD
Lenalidomide—Angina pectoris—Metformin—polycystic ovary syndrome	0.00291	0.0107	CcSEcCtD
Lenalidomide—Sweating increased—Metformin—polycystic ovary syndrome	0.00291	0.0107	CcSEcCtD
Lenalidomide—Abdominal discomfort—Metformin—polycystic ovary syndrome	0.00287	0.0106	CcSEcCtD
Lenalidomide—PTGS2—endometrium—polycystic ovary syndrome	0.00281	0.00744	CbGeAlD
Lenalidomide—Neutropenia—Metformin—polycystic ovary syndrome	0.0028	0.0103	CcSEcCtD
Lenalidomide—Upper respiratory tract infection—Metformin—polycystic ovary syndrome	0.00278	0.0102	CcSEcCtD
Lenalidomide—Infestation NOS—Metformin—polycystic ovary syndrome	0.00267	0.00983	CcSEcCtD
Lenalidomide—Infestation—Metformin—polycystic ovary syndrome	0.00267	0.00983	CcSEcCtD
Lenalidomide—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—BCL11A—polycystic ovary syndrome	0.00266	0.00764	CbGpPWpGaD
Lenalidomide—Neuropathy peripheral—Metformin—polycystic ovary syndrome	0.00261	0.00964	CcSEcCtD
Lenalidomide—PTGS2—uterus—polycystic ovary syndrome	0.00259	0.00686	CbGeAlD
Lenalidomide—PTGS2—pituitary gland—polycystic ovary syndrome	0.00254	0.00673	CbGeAlD
Lenalidomide—PTGS2—adipose tissue—polycystic ovary syndrome	0.00253	0.00671	CbGeAlD
Lenalidomide—Hepatobiliary disease—Metformin—polycystic ovary syndrome	0.00252	0.0093	CcSEcCtD
Lenalidomide—Bradycardia—Metformin—polycystic ovary syndrome	0.00244	0.00899	CcSEcCtD
Lenalidomide—Rhinitis—Metformin—polycystic ovary syndrome	0.0024	0.00885	CcSEcCtD
Lenalidomide—Hepatitis—Metformin—polycystic ovary syndrome	0.00239	0.00883	CcSEcCtD
Lenalidomide—TNFSF11—IL6-mediated signaling events—IL6—polycystic ovary syndrome	0.00239	0.00687	CbGpPWpGaD
Lenalidomide—Hypoaesthesia—Metformin—polycystic ovary syndrome	0.00238	0.00878	CcSEcCtD
Lenalidomide—ABCB1—embryo—polycystic ovary syndrome	0.00237	0.00629	CbGeAlD
Lenalidomide—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—NMNAT3—polycystic ovary syndrome	0.00237	0.00681	CbGpPWpGaD
Lenalidomide—Oedema peripheral—Metformin—polycystic ovary syndrome	0.00236	0.00869	CcSEcCtD
Lenalidomide—Connective tissue disorder—Metformin—polycystic ovary syndrome	0.00235	0.00867	CcSEcCtD
Lenalidomide—TNFSF11—Differentiation Pathway—IL6—polycystic ovary syndrome	0.00235	0.00675	CbGpPWpGaD
Lenalidomide—ABCB1—Drug Induction of Bile Acid Pathway—SULT2A1—polycystic ovary syndrome	0.00229	0.0066	CbGpPWpGaD
Lenalidomide—PTGS2—adrenal gland—polycystic ovary syndrome	0.00227	0.00602	CbGeAlD
Lenalidomide—Eye disorder—Metformin—polycystic ovary syndrome	0.00224	0.00825	CcSEcCtD
Lenalidomide—Cardiac disorder—Metformin—polycystic ovary syndrome	0.00222	0.00819	CcSEcCtD
Lenalidomide—Flushing—Metformin—polycystic ovary syndrome	0.00222	0.00819	CcSEcCtD
Lenalidomide—Angiopathy—Metformin—polycystic ovary syndrome	0.00217	0.00801	CcSEcCtD
Lenalidomide—Immune system disorder—Metformin—polycystic ovary syndrome	0.00216	0.00797	CcSEcCtD
Lenalidomide—Mediastinal disorder—Metformin—polycystic ovary syndrome	0.00216	0.00795	CcSEcCtD
Lenalidomide—Chills—Metformin—polycystic ovary syndrome	0.00215	0.00792	CcSEcCtD
Lenalidomide—PTGS2—female gonad—polycystic ovary syndrome	0.00212	0.00561	CbGeAlD
Lenalidomide—PTGS2—vagina—polycystic ovary syndrome	0.0021	0.00558	CbGeAlD
Lenalidomide—Erythema—Metformin—polycystic ovary syndrome	0.00208	0.00768	CcSEcCtD
Lenalidomide—Malnutrition—Metformin—polycystic ovary syndrome	0.00208	0.00768	CcSEcCtD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—AKT2—polycystic ovary syndrome	0.00207	0.00596	CbGpPWpGaD
Lenalidomide—Flatulence—Metformin—polycystic ovary syndrome	0.00205	0.00757	CcSEcCtD
Lenalidomide—Dysgeusia—Metformin—polycystic ovary syndrome	0.00204	0.00752	CcSEcCtD
Lenalidomide—Muscle spasms—Metformin—polycystic ovary syndrome	0.002	0.00739	CcSEcCtD
Lenalidomide—PTGS2—endocrine gland—polycystic ovary syndrome	0.00197	0.00522	CbGeAlD
Lenalidomide—Vision blurred—Metformin—polycystic ovary syndrome	0.00196	0.00724	CcSEcCtD
Lenalidomide—CDH5—Signaling by VEGF—AKT2—polycystic ovary syndrome	0.00196	0.00563	CbGpPWpGaD
Lenalidomide—Tremor—Metformin—polycystic ovary syndrome	0.00195	0.0072	CcSEcCtD
Lenalidomide—CDH5—Signaling events mediated by VEGFR1 and VEGFR2—VEGFA—polycystic ovary syndrome	0.00195	0.0056	CbGpPWpGaD
Lenalidomide—ABCB1—adrenal cortex—polycystic ovary syndrome	0.00195	0.00516	CbGeAlD
Lenalidomide—Ill-defined disorder—Metformin—polycystic ovary syndrome	0.00193	0.00713	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—ARHGAP23—polycystic ovary syndrome	0.00192	0.00552	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—ARHGAP30—polycystic ovary syndrome	0.00192	0.00552	CbGpPWpGaD
Lenalidomide—Malaise—Metformin—polycystic ovary syndrome	0.00188	0.00693	CcSEcCtD
Lenalidomide—Syncope—Metformin—polycystic ovary syndrome	0.00187	0.00689	CcSEcCtD
Lenalidomide—PTGS2—C-MYB transcription factor network—PTCRA—polycystic ovary syndrome	0.00185	0.00531	CbGpPWpGaD
Lenalidomide—Palpitations—Metformin—polycystic ovary syndrome	0.00184	0.00679	CcSEcCtD
Lenalidomide—Loss of consciousness—Metformin—polycystic ovary syndrome	0.00183	0.00675	CcSEcCtD
Lenalidomide—PTGS2—Prostaglandin Synthesis and Regulation—CYP11A1—polycystic ovary syndrome	0.00182	0.00523	CbGpPWpGaD
Lenalidomide—Hypertension—Metformin—polycystic ovary syndrome	0.0018	0.00663	CcSEcCtD
Lenalidomide—Chest pain—Metformin—polycystic ovary syndrome	0.00177	0.00654	CcSEcCtD
Lenalidomide—Myalgia—Metformin—polycystic ovary syndrome	0.00177	0.00654	CcSEcCtD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Metformin—polycystic ovary syndrome	0.00176	0.0065	CcSEcCtD
Lenalidomide—Discomfort—Metformin—polycystic ovary syndrome	0.00175	0.00646	CcSEcCtD
Lenalidomide—ABCB1—endometrium—polycystic ovary syndrome	0.00174	0.0046	CbGeAlD
Lenalidomide—Oedema—Metformin—polycystic ovary syndrome	0.0017	0.00627	CcSEcCtD
Lenalidomide—Infection—Metformin—polycystic ovary syndrome	0.00169	0.00623	CcSEcCtD
Lenalidomide—Shock—Metformin—polycystic ovary syndrome	0.00167	0.00617	CcSEcCtD
Lenalidomide—Nervous system disorder—Metformin—polycystic ovary syndrome	0.00167	0.00615	CcSEcCtD
Lenalidomide—Thrombocytopenia—Metformin—polycystic ovary syndrome	0.00166	0.00614	CcSEcCtD
Lenalidomide—Skin disorder—Metformin—polycystic ovary syndrome	0.00165	0.00609	CcSEcCtD
Lenalidomide—Hyperhidrosis—Metformin—polycystic ovary syndrome	0.00164	0.00606	CcSEcCtD
Lenalidomide—Anorexia—Metformin—polycystic ovary syndrome	0.00162	0.00598	CcSEcCtD
Lenalidomide—ABCB1—uterus—polycystic ovary syndrome	0.0016	0.00424	CbGeAlD
Lenalidomide—PTGS2—Overview of nanoparticle effects—BAX—polycystic ovary syndrome	0.0016	0.0046	CbGpPWpGaD
Lenalidomide—Hypotension—Metformin—polycystic ovary syndrome	0.00159	0.00586	CcSEcCtD
Lenalidomide—ABCB1—pituitary gland—polycystic ovary syndrome	0.00157	0.00417	CbGeAlD
Lenalidomide—ABCB1—adipose tissue—polycystic ovary syndrome	0.00157	0.00415	CbGeAlD
Lenalidomide—Musculoskeletal discomfort—Metformin—polycystic ovary syndrome	0.00155	0.00571	CcSEcCtD
Lenalidomide—Paraesthesia—Metformin—polycystic ovary syndrome	0.00153	0.00563	CcSEcCtD
Lenalidomide—Dyspnoea—Metformin—polycystic ovary syndrome	0.00152	0.00559	CcSEcCtD
Lenalidomide—Somnolence—Metformin—polycystic ovary syndrome	0.00151	0.00557	CcSEcCtD
Lenalidomide—Dyspepsia—Metformin—polycystic ovary syndrome	0.0015	0.00552	CcSEcCtD
Lenalidomide—Decreased appetite—Metformin—polycystic ovary syndrome	0.00148	0.00545	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Metformin—polycystic ovary syndrome	0.00147	0.00541	CcSEcCtD
Lenalidomide—Fatigue—Metformin—polycystic ovary syndrome	0.00147	0.00541	CcSEcCtD
Lenalidomide—Constipation—Metformin—polycystic ovary syndrome	0.00145	0.00536	CcSEcCtD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—FOXP3—polycystic ovary syndrome	0.00141	0.00407	CbGpPWpGaD
Lenalidomide—ABCB1—adrenal gland—polycystic ovary syndrome	0.0014	0.00372	CbGeAlD
Lenalidomide—Feeling abnormal—Metformin—polycystic ovary syndrome	0.0014	0.00517	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Metformin—polycystic ovary syndrome	0.00139	0.00513	CcSEcCtD
Lenalidomide—ABCB1—Constitutive Androstane Receptor Pathway—SULT2A1—polycystic ovary syndrome	0.00138	0.00398	CbGpPWpGaD
Lenalidomide—PTGS2—Overview of nanoparticle effects—CRP—polycystic ovary syndrome	0.00138	0.00397	CbGpPWpGaD
Lenalidomide—PTGS2—Prostaglandin Synthesis and Regulation—PRL—polycystic ovary syndrome	0.00136	0.00391	CbGpPWpGaD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—VEGFA—polycystic ovary syndrome	0.00135	0.0039	CbGpPWpGaD
Lenalidomide—Urticaria—Metformin—polycystic ovary syndrome	0.00135	0.00498	CcSEcCtD
Lenalidomide—Abdominal pain—Metformin—polycystic ovary syndrome	0.00134	0.00496	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—FLT4—polycystic ovary syndrome	0.00133	0.00383	CbGpPWpGaD
Lenalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—ATF1—polycystic ovary syndrome	0.00131	0.00378	CbGpPWpGaD
Lenalidomide—ABCB1—female gonad—polycystic ovary syndrome	0.00131	0.00347	CbGeAlD
Lenalidomide—ABCB1—vagina—polycystic ovary syndrome	0.0013	0.00345	CbGeAlD
Lenalidomide—CDH5—Signaling by VEGF—VEGFA—polycystic ovary syndrome	0.00128	0.00368	CbGpPWpGaD
Lenalidomide—Asthenia—Metformin—polycystic ovary syndrome	0.00122	0.0045	CcSEcCtD
Lenalidomide—ABCB1—endocrine gland—polycystic ovary syndrome	0.00122	0.00323	CbGeAlD
Lenalidomide—Pruritus—Metformin—polycystic ovary syndrome	0.0012	0.00444	CcSEcCtD
Lenalidomide—Diarrhoea—Metformin—polycystic ovary syndrome	0.00116	0.00429	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—NPB—polycystic ovary syndrome	0.00116	0.00335	CbGpPWpGaD
Lenalidomide—PTGS2—Arachidonic acid metabolism—AKR1C3—polycystic ovary syndrome	0.00114	0.00328	CbGpPWpGaD
Lenalidomide—Dizziness—Metformin—polycystic ovary syndrome	0.00112	0.00415	CcSEcCtD
Lenalidomide—Vomiting—Metformin—polycystic ovary syndrome	0.00108	0.00399	CcSEcCtD
Lenalidomide—Rash—Metformin—polycystic ovary syndrome	0.00107	0.00395	CcSEcCtD
Lenalidomide—Dermatitis—Metformin—polycystic ovary syndrome	0.00107	0.00395	CcSEcCtD
Lenalidomide—Headache—Metformin—polycystic ovary syndrome	0.00107	0.00393	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—PLEKHG5—polycystic ovary syndrome	0.00105	0.00303	CbGpPWpGaD
Lenalidomide—Nausea—Metformin—polycystic ovary syndrome	0.00101	0.00372	CcSEcCtD
Lenalidomide—PTGS2—Overview of nanoparticle effects—BCL2—polycystic ovary syndrome	0.000974	0.0028	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PTGER3—polycystic ovary syndrome	0.000971	0.00279	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—LHCGR—polycystic ovary syndrome	0.000971	0.00279	CbGpPWpGaD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—IL6—polycystic ovary syndrome	0.000937	0.0027	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PTAFR—polycystic ovary syndrome	0.000908	0.00261	CbGpPWpGaD
Lenalidomide—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—GAB1—polycystic ovary syndrome	0.000906	0.0026	CbGpPWpGaD
Lenalidomide—CDH5—Signaling by VEGF—IL6—polycystic ovary syndrome	0.000885	0.00254	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—ADRA1D—polycystic ovary syndrome	0.000882	0.00254	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—ADRA1B—polycystic ovary syndrome	0.000858	0.00247	CbGpPWpGaD
Lenalidomide—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—polycystic ovary syndrome	0.000836	0.0024	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—INHBB—polycystic ovary syndrome	0.000836	0.0024	CbGpPWpGaD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—IGFBP1—polycystic ovary syndrome	0.000795	0.00229	CbGpPWpGaD
Lenalidomide—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—NAMPT—polycystic ovary syndrome	0.000786	0.00226	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PDE3B—polycystic ovary syndrome	0.00078	0.00224	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—CYP1A1—polycystic ovary syndrome	0.000767	0.0022	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—INSR—polycystic ovary syndrome	0.000765	0.0022	CbGpPWpGaD
Lenalidomide—PTGS2—S1P1 pathway—VEGFA—polycystic ovary syndrome	0.000729	0.0021	CbGpPWpGaD
Lenalidomide—PTGS2—Arachidonic acid metabolism—CYP1A1—polycystic ovary syndrome	0.000717	0.00206	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—FSHR—polycystic ovary syndrome	0.000711	0.00204	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—FOXP3—polycystic ovary syndrome	0.000695	0.002	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—RACGAP1—polycystic ovary syndrome	0.000668	0.00192	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—CCNB1—polycystic ovary syndrome	0.000662	0.0019	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—PLAT—polycystic ovary syndrome	0.000658	0.00189	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—ADRA1A—polycystic ovary syndrome	0.00065	0.00187	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—FST—polycystic ovary syndrome	0.000633	0.00182	CbGpPWpGaD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—TFRC—polycystic ovary syndrome	0.000632	0.00182	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—ADRB3—polycystic ovary syndrome	0.000626	0.0018	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—LHB—polycystic ovary syndrome	0.000618	0.00178	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—GNRH1—polycystic ovary syndrome	0.000604	0.00174	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—TAB1—polycystic ovary syndrome	0.000601	0.00173	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—AKR1C1—polycystic ovary syndrome	0.000585	0.00168	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—SCT—polycystic ovary syndrome	0.000579	0.00167	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—MTNR1B—polycystic ovary syndrome	0.000553	0.00159	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—FST—polycystic ovary syndrome	0.00055	0.00158	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—FGF18—polycystic ovary syndrome	0.000543	0.00156	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PPARG—polycystic ovary syndrome	0.000542	0.00156	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—RBP4—polycystic ovary syndrome	0.000539	0.00155	CbGpPWpGaD
Lenalidomide—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—polycystic ovary syndrome	0.000523	0.0015	CbGpPWpGaD
Lenalidomide—PTGS2—Overview of nanoparticle effects—IL6—polycystic ovary syndrome	0.000504	0.00145	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—YAP1—polycystic ovary syndrome	0.000503	0.00145	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—NCOR1—polycystic ovary syndrome	0.0005	0.00144	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—GAB1—polycystic ovary syndrome	0.000496	0.00143	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—LPCAT2—polycystic ovary syndrome	0.000482	0.00139	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—INSR—polycystic ovary syndrome	0.000474	0.00136	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—NGFR—polycystic ovary syndrome	0.000458	0.00132	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—AKR1C3—polycystic ovary syndrome	0.000451	0.0013	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—TNRC6B—polycystic ovary syndrome	0.000444	0.00128	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PGR—polycystic ovary syndrome	0.000439	0.00126	CbGpPWpGaD
Lenalidomide—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—MTHFR—polycystic ovary syndrome	0.000429	0.00123	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—MTHFR—polycystic ovary syndrome	0.000425	0.00122	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—GHRL—polycystic ovary syndrome	0.000408	0.00117	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PLAT—polycystic ovary syndrome	0.000408	0.00117	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—CRP—polycystic ovary syndrome	0.000405	0.00116	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—ABCB6—polycystic ovary syndrome	0.000399	0.00115	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—FST—polycystic ovary syndrome	0.00039	0.00112	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—ATF1—polycystic ovary syndrome	0.000389	0.00112	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—TEAD2—polycystic ovary syndrome	0.000381	0.0011	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—AKR1C2—polycystic ovary syndrome	0.000381	0.0011	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TOP2A—polycystic ovary syndrome	0.000381	0.0011	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—TCF7L2—polycystic ovary syndrome	0.00038	0.00109	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—NGFR—polycystic ovary syndrome	0.000359	0.00103	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—polycystic ovary syndrome	0.000359	0.00103	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PRL—polycystic ovary syndrome	0.000356	0.00102	CbGpPWpGaD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—LEP—polycystic ovary syndrome	0.000353	0.00102	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—INS—polycystic ovary syndrome	0.000338	0.000973	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—ADRB2—polycystic ovary syndrome	0.000338	0.000972	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PNPLA2—polycystic ovary syndrome	0.000319	0.000919	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—GNAS—polycystic ovary syndrome	0.000313	0.000901	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—LEP—polycystic ovary syndrome	0.000313	0.000901	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—SERPINE1—polycystic ovary syndrome	0.000311	0.000894	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—SRD5A1—polycystic ovary syndrome	0.000303	0.000871	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—NCOR1—polycystic ovary syndrome	0.000298	0.000858	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—BCL2—polycystic ovary syndrome	0.000296	0.000853	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—AR—polycystic ovary syndrome	0.000296	0.000852	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—NRG1—polycystic ovary syndrome	0.000293	0.000843	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—STAR—polycystic ovary syndrome	0.000289	0.000831	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—TRPV6—polycystic ovary syndrome	0.000284	0.000817	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—NMNAT3—polycystic ovary syndrome	0.00028	0.000806	CbGpPWpGaD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—SERPINE1—polycystic ovary syndrome	0.000277	0.000797	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TOP2A—polycystic ovary syndrome	0.00027	0.000777	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—SCNN1A—polycystic ovary syndrome	0.000257	0.000739	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—BAX—polycystic ovary syndrome	0.000252	0.000726	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—IRS2—polycystic ovary syndrome	0.000251	0.000722	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—HSD3B1—polycystic ovary syndrome	0.000246	0.000706	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—LEP—polycystic ovary syndrome	0.000246	0.000706	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—NMNAT3—polycystic ovary syndrome	0.000235	0.000675	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—LHB—polycystic ovary syndrome	0.000224	0.000644	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—IRS1—polycystic ovary syndrome	0.000219	0.00063	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—HSD3B2—polycystic ovary syndrome	0.000219	0.00063	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—SUOX—polycystic ovary syndrome	0.000215	0.000618	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—LPCAT2—polycystic ovary syndrome	0.000215	0.000618	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—AKR1C1—polycystic ovary syndrome	0.000212	0.00061	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—POMC—polycystic ovary syndrome	0.000211	0.000607	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—AR—polycystic ovary syndrome	0.00021	0.000604	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—INS—polycystic ovary syndrome	0.00021	0.000603	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—IGF1—polycystic ovary syndrome	0.000203	0.000584	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—AKT2—polycystic ovary syndrome	0.000203	0.000583	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—ISYNA1—polycystic ovary syndrome	0.0002	0.000574	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—SULT2A1—polycystic ovary syndrome	0.000195	0.000561	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—SERPINE1—polycystic ovary syndrome	0.000193	0.000554	CbGpPWpGaD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—VEGFA—polycystic ovary syndrome	0.000191	0.000549	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—YAP1—polycystic ovary syndrome	0.000182	0.000524	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—BAX—polycystic ovary syndrome	0.000179	0.000514	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—IGF1—polycystic ovary syndrome	0.000176	0.000506	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—CYP11A1—polycystic ovary syndrome	0.000173	0.000497	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—TEAD2—polycystic ovary syndrome	0.00017	0.000488	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—AKR1C2—polycystic ovary syndrome	0.00017	0.000488	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—NMNAT3—polycystic ovary syndrome	0.000166	0.000479	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—VEGFA—polycystic ovary syndrome	0.000165	0.000475	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—AKR1C3—polycystic ovary syndrome	0.000163	0.000469	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—CYP17A1—polycystic ovary syndrome	0.000161	0.000462	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—BCL2—polycystic ovary syndrome	0.000154	0.000442	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—LPCAT2—polycystic ovary syndrome	0.000152	0.000438	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—SUOX—polycystic ovary syndrome	0.000152	0.000438	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—IL6—polycystic ovary syndrome	0.000148	0.000425	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—RPL37A—polycystic ovary syndrome	0.000144	0.000415	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PNPLA2—polycystic ovary syndrome	0.000142	0.000409	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—ISYNA1—polycystic ovary syndrome	0.000142	0.000407	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—HMMR—polycystic ovary syndrome	0.000137	0.000394	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—SRD5A1—polycystic ovary syndrome	0.000135	0.000388	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—VEGFA—polycystic ovary syndrome	0.000133	0.000381	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—STAR—polycystic ovary syndrome	0.000129	0.00037	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—CYP19A1—polycystic ovary syndrome	0.000127	0.000366	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—polycystic ovary syndrome	0.000125	0.000359	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—AKR1C2—polycystic ovary syndrome	0.00012	0.000346	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—TEAD2—polycystic ovary syndrome	0.00012	0.000346	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—IL6—polycystic ovary syndrome	0.000117	0.000336	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—polycystic ovary syndrome	0.000115	0.000331	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—HMMR—polycystic ovary syndrome	0.000115	0.00033	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—AKR1C1—polycystic ovary syndrome	0.000113	0.000324	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—HSD3B1—polycystic ovary syndrome	0.000109	0.000315	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—polycystic ovary syndrome	0.000109	0.000313	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—NCOR1—polycystic ovary syndrome	0.000108	0.000311	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—TFRC—polycystic ovary syndrome	0.000107	0.000308	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—FGF18—polycystic ovary syndrome	0.000105	0.000301	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—RBP4—polycystic ovary syndrome	0.000104	0.000298	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—CYP1A1—polycystic ovary syndrome	0.000102	0.000295	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PNPLA2—polycystic ovary syndrome	0.000101	0.00029	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—LHB—polycystic ovary syndrome	9.97e-05	0.000287	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—PLAT—polycystic ovary syndrome	9.97e-05	0.000287	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—HSD3B2—polycystic ovary syndrome	9.75e-05	0.00028	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—SRD5A1—polycystic ovary syndrome	9.56e-05	0.000275	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—GAB1—polycystic ovary syndrome	9.55e-05	0.000275	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—AKR1C1—polycystic ovary syndrome	9.44e-05	0.000272	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—NAMPT—polycystic ovary syndrome	9.31e-05	0.000268	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—IL6—polycystic ovary syndrome	9.17e-05	0.000264	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—STAR—polycystic ovary syndrome	9.12e-05	0.000262	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—SLC2A4—polycystic ovary syndrome	9.12e-05	0.000262	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—SULT2A1—polycystic ovary syndrome	8.69e-05	0.00025	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—AKR1C3—polycystic ovary syndrome	8.68e-05	0.00025	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—TNRC6B—polycystic ovary syndrome	8.54e-05	0.000246	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—RRM2—polycystic ovary syndrome	8.42e-05	0.000242	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—polycystic ovary syndrome	8.15e-05	0.000234	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—HMMR—polycystic ovary syndrome	8.13e-05	0.000234	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—YAP1—polycystic ovary syndrome	8.11e-05	0.000233	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—NAMPT—polycystic ovary syndrome	7.79e-05	0.000224	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—HSD3B1—polycystic ovary syndrome	7.75e-05	0.000223	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	7.75e-05	0.000223	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CYP11A1—polycystic ovary syndrome	7.7e-05	0.000221	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—GNAS—polycystic ovary syndrome	7.65e-05	0.00022	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	7.64e-05	0.00022	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—TCF7L2—polycystic ovary syndrome	7.32e-05	0.00021	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—AKR1C3—polycystic ovary syndrome	7.27e-05	0.000209	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—SLC2A4—polycystic ovary syndrome	7.19e-05	0.000207	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CYP17A1—polycystic ovary syndrome	7.16e-05	0.000206	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—LHB—polycystic ovary syndrome	7.07e-05	0.000203	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—HSD3B2—polycystic ovary syndrome	6.91e-05	0.000199	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PRL—polycystic ovary syndrome	6.86e-05	0.000197	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—AKR1C1—polycystic ovary syndrome	6.69e-05	0.000193	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—TH—polycystic ovary syndrome	6.19e-05	0.000178	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—SULT2A1—polycystic ovary syndrome	6.16e-05	0.000177	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—SLC2A4—polycystic ovary syndrome	6.02e-05	0.000173	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—RRM2—polycystic ovary syndrome	5.97e-05	0.000172	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—YAP1—polycystic ovary syndrome	5.75e-05	0.000165	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—NCOR1—polycystic ovary syndrome	5.75e-05	0.000165	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CYP19A1—polycystic ovary syndrome	5.66e-05	0.000163	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—NRG1—polycystic ovary syndrome	5.64e-05	0.000162	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—NAMPT—polycystic ovary syndrome	5.52e-05	0.000159	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CYP11A1—polycystic ovary syndrome	5.46e-05	0.000157	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—AKR1C3—polycystic ovary syndrome	5.15e-05	0.000148	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—MTHFR—polycystic ovary syndrome	5.08e-05	0.000146	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CYP17A1—polycystic ovary syndrome	5.07e-05	0.000146	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—GNAS—polycystic ovary syndrome	5.05e-05	0.000145	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—IRS2—polycystic ovary syndrome	4.83e-05	0.000139	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—NCOR1—polycystic ovary syndrome	4.82e-05	0.000138	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CYP1A1—polycystic ovary syndrome	4.56e-05	0.000131	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—TH—polycystic ovary syndrome	4.39e-05	0.000126	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—SLC2A4—polycystic ovary syndrome	4.27e-05	0.000123	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—MTHFR—polycystic ovary syndrome	4.26e-05	0.000122	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—IRS1—polycystic ovary syndrome	4.22e-05	0.000121	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—INS—polycystic ovary syndrome	4.04e-05	0.000116	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CYP19A1—polycystic ovary syndrome	4.01e-05	0.000115	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—AKT2—polycystic ovary syndrome	3.91e-05	0.000112	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—SERPINE1—polycystic ovary syndrome	3.71e-05	0.000107	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GNAS—polycystic ovary syndrome	3.58e-05	0.000103	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PPARG—polycystic ovary syndrome	3.45e-05	9.92e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—NCOR1—polycystic ovary syndrome	3.41e-05	9.82e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—POMC—polycystic ovary syndrome	3.4e-05	9.79e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—INS—polycystic ovary syndrome	3.38e-05	9.73e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CYP1A1—polycystic ovary syndrome	3.24e-05	9.31e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—MTHFR—polycystic ovary syndrome	3.02e-05	8.68e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PPARG—polycystic ovary syndrome	2.45e-05	7.04e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—POMC—polycystic ovary syndrome	2.41e-05	6.94e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—INS—polycystic ovary syndrome	2.4e-05	6.9e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—IL6—polycystic ovary syndrome	1.77e-05	5.08e-05	CbGpPWpGaD
